Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer

K. Matsui; N. Masuda; M. Fukuoka; T. Yana; T. Hirashima; T. Komiya; M. Kobayashi; M. Kawahara; S. Atagi; M. Ogawara; S. Negoro; S. Kudoh; K. Furuse

doi:10.1038/bjc.1998.325

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer

K. Matsui
, N. Masuda
, M. Fukuoka
, T. Yana
, T. Hirashima
, T. Komiya
, M. Kobayashi
, M. Kawahara
, S. Atagi
, M. Ogawara
, S. Negoro
, S. Kudoh
, K. Furuse

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.

Original language	English (US)
Pages (from-to)	1961-1965
Number of pages	5
Journal	British Journal of Cancer
Volume	77
Issue number	11
DOIs	https://doi.org/10.1038/bjc.1998.325
State	Published - Jun 1998

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

All Science Journal Classification (ASJC) codes

Oncology
Cancer Research

Access to Document

10.1038/bjc.1998.325

Cite this

@article{719b543e8ef74148b59cecfd34da733a,

title = "Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer",

abstract = "A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81\%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.",

author = "K. Matsui and N. Masuda and M. Fukuoka and T. Yana and T. Hirashima and T. Komiya and M. Kobayashi and M. Kawahara and S. Atagi and M. Ogawara and S. Negoro and S. Kudoh and K. Furuse",

note = "Funding Information: This work was supported in part by a Grant-in-Aid for Cancer Research from the Japanese Ministry of Health and Welfare (7-23) and a grant from Bristol-Myers Squibb (Tokyo, Japan). We wish to thank Mr Seiji Ito, Oncology Department staff. Bristol-Myers Squibb, Tokyo, Japan, for his help in the data collection and analysis and Dr Luigi Lenaz, Medical Doctor, Bristol-Myers Squibb, Princeton, NJ, USA, for critically reviewing multiple drafts of the manuscript.",

year = "1998",

month = jun,

doi = "10.1038/bjc.1998.325",

language = "English (US)",

volume = "77",

pages = "1961--1965",

journal = "British Journal of Cancer",

issn = "0007-0920",

publisher = "Springer Nature",

number = "11",

}

TY - JOUR

T1 - Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer

AU - Matsui, K.

AU - Masuda, N.

AU - Fukuoka, M.

AU - Yana, T.

AU - Hirashima, T.

AU - Komiya, T.

AU - Kobayashi, M.

AU - Kawahara, M.

AU - Atagi, S.

AU - Ogawara, M.

AU - Negoro, S.

AU - Kudoh, S.

AU - Furuse, K.

N1 - Funding Information: This work was supported in part by a Grant-in-Aid for Cancer Research from the Japanese Ministry of Health and Welfare (7-23) and a grant from Bristol-Myers Squibb (Tokyo, Japan). We wish to thank Mr Seiji Ito, Oncology Department staff. Bristol-Myers Squibb, Tokyo, Japan, for his help in the data collection and analysis and Dr Luigi Lenaz, Medical Doctor, Bristol-Myers Squibb, Princeton, NJ, USA, for critically reviewing multiple drafts of the manuscript.

PY - 1998/6

Y1 - 1998/6

N2 - A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.

AB - A phase II trial was conducted to evaluate the efficacy and toxicity of the Egorin's carboplatin dosing formula with 14-day oral etoposide in 38 elderly patients with small-cell lung cancer (SCLC). The overall response rate was 81%. Median survival times were 15.1 months for 16 limited-disease (LD) and 8.6 months for 22 extensive-disease (ED) patients. Myelosuppression was the principal side-effect. This regimen is an active regimen in the treatment of elderly SCLC patients.

UR - https://www.scopus.com/pages/publications/0031799126

UR - https://www.scopus.com/pages/publications/0031799126#tab=citedBy

U2 - 10.1038/bjc.1998.325

DO - 10.1038/bjc.1998.325

M3 - Article

C2 - 9667675

AN - SCOPUS:0031799126

SN - 0007-0920

VL - 77

SP - 1961

EP - 1965

JO - British Journal of Cancer

JF - British Journal of Cancer

IS - 11

ER -

Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer

Abstract

UN SDGs

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this